Non-inclusion complexes between riboflavin and cyclodextrins

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 6, 2012, Pages 832-842

  De Jesus, Marcelo Bispo ^a   Fraceto, Leonardo Fernandes ^a,b   Martini, Maria Florencia ^c   Pickholz, Monica ^a,c   Ferreira, Carmen Veríssima ^a   De Paula, Eneida ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

cyclodextrin; NMR; non inclusion complex; prostate cancer; riboflavin

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BETA CYCLODEXTRIN; RIBOFLAVIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG SOLUBILITY; HUMAN; HUMAN CELL; HYDROGEN BOND; MALE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NUCLEAR OVERHAUSER EFFECT; PHYSICAL CHEMISTRY; PROSTATE CANCER;

ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; CELL LINE, TUMOR; DRUG CARRIERS; HUMANS; HYDROGEN BONDING; MALE; PROSTATIC NEOPLASMS; RIBOFLAVIN; SOLUBILITY;

EID: 84861099954     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01492.x     Document Type: Article

References (51)

1. Jemal A, et al,. Cancer statistics, 2010. CA Cancer J Clin 2010; 5: 277-300.
2. Malvezzi M, et al,. European cancer mortality predictions for the year 2011. Ann Oncol 2011; 4: 947-956.
3. Zelefsky MJ, et al,. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J Clin Oncol 2010; 9: 1508-1513.
4. Souza ACS, et al,. A promising action of riboflavin as a mediator of leukaemia cell death. Apoptosis 2006; 10: 1761-1771. (Pubitemid 44376244)
5. de Souza Queiroz KC, et al,. A possible anti-proliferative and anti-metastatic effect of irradiated riboflavin in solid tumours. Cancer Lett 2007; 1: 126-134.
6. Figueiredo JC, et al,. Vitamins B2, B6, and B12 and risk of new colorectal adenomas in a randomized trial of aspirin use and folic acid supplementation. Cancer Epidemiol Biomarkers Prev 2008; 8: 2136-2145.
7. Aniceto C, et al,. Determinação Espectrofotométrica de Vitamina B2 (Riboflavina) em FormulaçAμes Farmacêuticas Empregando Sistema de Análises por Injeção em Fluxo. Quim Nova 2000; 5: 637-640.
8. Ball GFM,. Vitamins. Their Role in the Human Body. London: Blackwell Publishing, 2004.
9. Laza-Knoerr AL, et al,. Cyclodextrins for drug delivery. J Drug Target 2010; 9: 645-656.
10. Mohamed MH, et al,. Electrospray ionization mass spectrometry studies of cyclodextrin-carboxylate ion inclusion complexes. Rapid Commun Mass Spectrom 2009; 23: 3703-3712.
11. Ribeiro RR, et al,. Prolonged absorption of antimony(V) by the oral route from non-inclusion meglumine antimoniate-beta-cyclodextrin conjugates. Biopharm Drug Dispos 2010; 2-3: 109-119.
12. Messner M, et al,. Self-assembled cyclodextrin aggregates and nanoparticles. Int J Pharm 2010; 1-2: 199-208.
13. Jansook P, et al,. yCD/HPyCD mixtures as solubilizer: solid-state characterization and sample dexamethasone eye drop suspension. J Pharm Pharm Sci 2010; 3: 336-350.
14. Higuchi T, Connors KA,. Phase-solubility techniques. Adv Anal Chem Instrum 1965; 117: 117-212.
15. Matsui Y, Tokunaga S,. Internal reference compounds available for the determination of binding constants for cyclodextrin complexes by 1H NMR spectrometry. Bull Chem Soc Jpn 1996; 9: 2477-2480. (Pubitemid 126476784)
16. Johnson CS Jr,. Diffusion ordered nuclear magnetic resonance spectroscopy: principles and applications. Prog Nucl Magn Reson Spectrosc 1999; 34: 203-256. (Pubitemid 129595218)
17. Schneider HJ, et al,. NMR studies of cyclodextrins and cyclodextrin complexes. Chem Rev 1998; 5: 1755-1786.
18. Berendsen HJC, et al,. Gromacs-a message-passing parallel molecular-dynamics implementation. Comput Phys Commun 1995; 1-3: 43-56.
19. Lindahl E, et al,. GROMACS 3.0: a package for molecular simulation and trajectory analysis. J Mol Model 2001; 8: 306-317. (Pubitemid 36153547)
20. Van der Spoel D, et al,. GROMACS: fast, flexible, and free. J Comput Chem 2005; 16: 1701-1718. (Pubitemid 43076182)
21. Hess B, et al,. GROMACS 4: algorithms for highly efficient, load-balanced, and scalable molecular simulation. J Chem Theory Comput 2008; 3: 435-447.
22. Oostenbrink C, et al,. A biomolecular force field based on the free enthalpy of hydration and solvation: the GROMOS force-field parameter sets 53A5 and 53A6. J Comput Chem 2004; 13: 1656-1676.
23. Darden T, et al,. Particle mesh Ewald: an N [center-dot] log(N) method for Ewald sums in large systems. J Chem Phys 1993; 12: 10089-10092.
24. Essmann U, et al,. A smooth particle mesh Ewald method. J Chem Phys 1995; 19: 8577-8593.
25. Berendsen HJC, et al,. Molecular dynamics with coupling to an external bath. J Chem Phys 1984; 8: 3684-3690.
26. Martínez JM, Martínez L,. Packing optimization for automated generation of complex system's initial configurations for molecular dynamics and docking. J Comput Chem 2003; 7: 819-825.
27. Hermans J, et al,. A consistent empirical potential for water-protein interactions. Biopolymers 1984; 8: 1513-1518.
28. Mosmann T,. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 1-2: 55-63. (Pubitemid 14203433)
29. Szejtli J,. Cyclodextrin Technology. Dordrecht: Kluwer Academic Publishers, 1998.
30. Terekhova I, et al,. Inclusion complex formation of α- and β-cyclodextrins with riboflavin and alloxazine in aqueous solution: thermodynamic study. J Incl Phenom Macrocycl Chem 2011; 1: 167-172.
31. Zielenkiewicz W, et al,. Thermodynamic study on inclusion complex formation of riboflavin with hydroxypropyl-β-cyclodextrin in water. J Therm Anal Calorim 2010; 2: 595-600.
32. Loftsson T, et al,. Self-association and cyclodextrin solubilization of drugs. J Pharm Sci 2002; 11: 2307-2316. (Pubitemid 35231194)
33. Bekers O, et al,. Cyclodextrins in the pharmaceutical field. Drug Dev Ind Pharm 1991; 17: 1503-1549.
34. Wang XM, Chen HY,. A spectroelectrochemical study of the interaction of riboflavin with beta-cyclodextrin. Spectrochim Acta A Mol Biomol Spectrosc 1996; 51: 599-605.
35. de Jesus MB, et al,. Improvement of the oral praziquantel anthelmintic effect by cyclodextrin complexation. J Drug Target 2010; 1: 21-26.
36. Giordano F, et al,. Thermal analysis of cyclodextrins and their inclusion compounds. Thermochim Acta 2001; 2: 123-151. (Pubitemid 33100003)
37. Ramamurthy V, Eaton DF,. Photochemistry and photophysics within cyclodextrin cavities. Acc Chem Res 1988; 8: 300-306.
38. de Jesus MB, et al,. Theoretical and experimental study of a praziquantel and beta-cyclodextrin inclusion complex using molecular mechanic calculations and H1-nuclear magnetic resonance. J Pharm Biomed Anal 2006; 4: 1428-1432.
39. Cabeca LF, et al,. Topology of a ternary complex (proparacaine-beta- cyclodextrin-liposome) by STD NMR. Magn Reson Chem 2008; 9: 832-837.
40. de Araujo DR, et al,. Development and pharmacological evaluation of ropivacaine-2-hydroxypropyl-beta-cyclodextrin inclusion complex. Eur J Pharm Sci 2008; 1: 60-71.
41. Grillo R, et al,. Study of the interaction between hydroxymethylnitrofurazone and 2-hydroxypropyl-beta-cyclodextrin. J Pharm Biomed Anal 2008; 2: 295-302.
42. Edwards AM, et al,. Photochemical and pharmacokinetic properties of selected flavins. J Photochem Photobiol B 1999; 1: 36-41. (Pubitemid 29132262)
43. Williamson G, et al,. 1H NMR spectral analysis of the ribityl side chain of riboflavin and its ring-substituted analogs. Methods Enzymol 1986; 122: 240-248. (Pubitemid 16017513)
44. Chienthavorn O, et al,. Superheated water chromatography-nuclear magnetic resonance spectroscopy and mass spectrometry of vitamins. J Pharm Biomed Anal 2004; 3: 477-482. (Pubitemid 39441316)
45. Pinto LM, et al,. Physico-chemical characterization of benzocaine-beta-cyclodextrin inclusion complexes. J Pharm Biomed Anal 2005; 5: 956-963. (Pubitemid 41441724)
46. Moraes CM, et al,. Study of the interaction between S(-) bupivacaine and 2-hydroxypropyl-beta-cyclodextrin. Int J Pharm 2007; 1: 99-106.
47. Macomber RS,. A Complete Introduction to Modern NMR Spectroscopy. New York: John Wiley & Sons, 1998.
48. Fraceto LF, et al,. Characterization of the inclusion complex ropivacaine: beta-cyclodextrin. Quim Nova 2007; 5: 1203-1207.
49. Morris KF, Johnson CS,. Diffusion-ordered two-dimensional nuclear magnetic resonance spectroscopy. J Am Chem Soc 1992; 8: 3139-3141.
50. Bareford LM, et al,. Intracellular processing of riboflavin in human breast cancer cells. Mol Pharm 2008; 5: 839-848.
51. Loftsson T, Brewster ME,. Pharmaceutical applications of cyclodextrins: effects on drug permeation through biological membranes. J Pharm Pharmacol 2011; 63: 1119-1135.